Page last updated: 2024-12-06
n-myristoylglycine
Description
N-myristoylglycine (MyrGly) is a fatty acid amide that is a component of the myristoylated protein N-myristoyltransferase (NMT) enzyme, which catalyzes the attachment of myristate to proteins. MyrGly is a potent inhibitor of NMT and has been shown to have anti-inflammatory and anti-cancer effects. The compound is also a substrate for the enzyme fatty acid amide hydrolase (FAAH), which is responsible for the breakdown of fatty acid amides. MyrGly has been studied for its potential therapeutic applications in the treatment of inflammatory diseases, cancer, and other conditions. It is synthesized by the reaction of myristoyl chloride with glycine in the presence of a base. The synthesis and biological activity of MyrGly have been investigated in several studies, and it has been shown to be a promising drug candidate for various diseases.'
N-myristoylglycine: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
N-myristoylglycine : An N-acylglycine in which the acyl group is specified as myristoyl (tetradecanoyl). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 72348 |
| CHEMBL ID | 4854669 |
| CHEBI ID | 87142 |
| SCHEMBL ID | 343546 |
| MeSH ID | M0160630 |
Synonyms (35)
| Synonym |
|---|
| nsc-622050 |
| nsc622050 |
| n-myristoylglycine |
| 2-(tetradecanoylamino)acetic acid |
| 14246-55-0 |
| n-tetradecanoylglycine |
| glycine,n-(1-oxotetradecyl)- |
| 84uk82t430 , |
| unii-84uk82t430 |
| glycine, n-(1-oxotetradecyl)- |
| n-myristoyl-gly |
| FT-0637042 |
| SCHEMBL343546 |
| myristoyl-gly-oh |
| tetradecanoylglycine |
| CHEBI:87142 |
| myristoylglycine |
| DTXSID10162047 |
| n-(1-oxotetradecyl)glycine |
| n-myristoyl glycine |
| 2-tetradecanamidoacetic acid |
| myristoyl-gly-oh, aldrichcpr |
| mfcd00155627 |
| n-myristoyl-glycine |
| AKOS027328012 |
| n-myristoylglycine, analytical reference material |
| myristoyl glycine |
| J-007658 |
| acylglycine c:14 |
| Q27159399 |
| CS-0111612 |
| FD21630 |
| ?myristoyl glycine |
| CHEMBL4854669 |
| mryistoyl-gly-oh |
Roles (2)
| Role | Description |
|---|
| human urinary metabolite | Any metabolite (endogenous or exogenous) found in human urine samples. |
| human blood serum metabolite | Any metabolite (endogenous or exogenous) found in human blood serum samples. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (2)
| Class | Description |
|---|
| N-acylglycine | An N-acyl-amino acid in which amino acid specified is glycine. |
| fatty amide | A monocarboxylic acid amide derived from a fatty acid. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (6)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 2 (33.33) | 18.7374 |
| 1990's | 2 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.72
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 12.72 (24.57) | | Research Supply Index | 1.95 (2.92) | | Research Growth Index | 4.66 (4.65) | | Search Engine Demand Index | 0.00 (26.88) | | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |